Key Highlights
- Bioventix plc (LSE:BVXP) shares rose 4.48% on Wednesday 30 September 2026.
- The company's full-year results for the year to 30 June 2026 are expected in the coming weeks, typically in late October.
- Management had guided to a modest Revenue decline in the 2025-26 year due to headwinds in China, with growth expected from neurology and wider troponin use.
- An Interim Dividend of 70p per share was paid in April 2026, and the trailing Dividend Yield is high by market standards.
- Neurology antibodies, including those developed with the University of Gothenburg for Alzheimer's testing, are the key Long-term Growth driver.
Bioventix (LSE:BVXP) Moves Higher
Shares in Bioventix plc (LSE:BVXP), the Farnham-based specialist in high-affinity monoclonal antibodies for clinical diagnostics, rose 4.48% on Wednesday. The gain comes as investors position ahead of the company's annual results and follows a period of share price weakness that pushed the dividend yield to unusually high levels.
Why Bioventix Shares Are in Focus
Bioventix creates antibodies that are used in blood tests run on large diagnostic analysers made by global healthcare companies. It earns money in two ways: by selling physical antibody supplies and by collecting royalties on tests that use its antibodies. Royalties make up the bulk of revenue, which is why profit margins are exceptionally high, with pre-tax profit typically around three-quarters of revenue.
Its best-known product is a vitamin D antibody, which has long been its largest revenue stream. It also earns royalties on high-sensitivity troponin tests used to diagnose heart attacks, as well as antibodies for hormones and other markers.
The company is famous among UK income investors for returning almost all of its profits as dividends. For the year to June 2025, it paid total dividends of 150p per share, and a further 70p interim dividend was paid in April 2026.
Key Reasons Behind the 4.48% Gain Today
The first reason is positioning ahead of results. Bioventix usually reports full-year results in late October, alongside its second interim dividend. Investors are buying ahead of the announcement, hoping for evidence that the expected revenue decline has been contained and that neurology sales are gaining momentum.
The second reason is the neurology opportunity. Bioventix has developed antibodies targeting tau proteins, including p-tau217, in collaboration with the University of Gothenburg. Blood tests for Alzheimer's disease are moving from research use to clinical settings, and if these assays gain wide adoption the Royalty stream could become significant. Large-scale production of some neurology antibodies has already begun.
The third reason is income appeal. After a period of share price weakness, the dividend yield has risen to levels that attract income-focused investors, especially as bond yields eased on Wednesday following softer US Inflation data.
The fourth Factor is troponin growth potential. Management has said it expects troponin revenue growth from 2026 onwards as testing expands beyond the traditional acute chest pain setting, supported by an updated US label for a partner's high-sensitivity troponin assay.
Headwinds in China
The company's recent results have been held back by China, where government cost-reduction policies and a push for local Manufacturing have squeezed Demand for imported diagnostic components. In the year to June 2025, revenue fell 4% to £13.1 million and pre-tax profit declined 5% to £10.1 million. Management warned of a modest further revenue decline in 2025-26 because of continuing headwinds in the historic core business. Investors should also note that royalties from one major troponin partner are contractually due to end in June 2032.
What Investors Are Watching Next
Key catalysts include full-year results and the second interim dividend, updates on neurology antibody sales and clinical adoption of Alzheimer's blood tests, troponin royalty trends and China market conditions. Risks include further weakness in China, foreign exchange movements, customer concentration and the timing of new royalty streams.






Please wait processing your request...